About
Looking for more information?
Contact our responsive and friendly client services team any time.
INVESTOR PRESENTATION - ACTINOGEN MEDICAL LIMITED
ACTINOGEN MEDICAL LIMITED
Health Care
Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management. Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease. Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.
Read moreMarket Cap
24.56m
Price at Close
$0.022
4w avg. Volume
3.74m
4w avg. Turnover
$91.97k
Announcements
| announcement | t+2 movement | date |
|---|---|---|
| - | 22 Oct 2020 |
| - | 22 Oct 2020 |
| -8.00% | 16 Oct 2020 |
| 0.00% | 15 Oct 2020 |
| -10.71% | 14 Oct 2020 |
| -10.71% | 14 Oct 2020 |
| -10.71% | 14 Oct 2020 |
| -10.71% | 14 Oct 2020 |
| 0.00% | 12 Oct 2020 |
| +3.57% | 01 Oct 2020 |
Market Data
Current Price
$0.022
52WK HIGH
$0.056
52WK LOW
$0.015
1YR RETURN
-48.84%
1YR RETURN VS. SECTOR
-72.29%
90 DAY RETURN
-4.35%
ASX RANK
1,368
/2,010
SECTOR RANK
36
/47
SHARES OUTSTANDING
1.12b
ACTINOGEN MEDICAL LIMITED
Health Care
Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management. Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease. Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.
Read moreMarket Cap
24.56m
Price at Close
$0.022
4w avg. Volume
3.74m
4w avg. Turnover
$91.97k
ASX:ACW is not raising right now
Want to invest?
Contact Us
(03) 9028 2888
clients@freshequities.com
Address
Level 7, 388 Bourke St
Melbourne VIC 3000
Australia